Neurological Disorders News
-
Showcase
Empatica Announces EmbracePlus: NASA Medical Quality in a Down-to-Earth Smart Watch
BOSTON, Nov. 19, 2019 /PRNewswire/ -- On November 19th, 2019, Empatica is announcing EmbracePlus, their new smart watch built in partnership with TRISH, the Translational Research Institute for Space Health. NASA's Human Research Program partners with external entities to develop new approaches that can help reduce the risk to humans on long exploration missions. One such entity is TRISH, who ...
-
CD BioSciences Announces Comprehensive Range of Nervous System Tissue Microarrays
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technologies, proudly announces an extensive portfolio of Nervous System Tissue Microarrays designed to support neuroscience research. This comprehensive collection provides researchers with a unique resource to study various neurological conditions and accelerate their investigations into neurological ...
-
Microneedle Market Projected to Reach $1.3 Billion by 2028, Reveals Latest BCC Research Study
Boston: Microneedle technology, driven by high demand in dermatologic procedures and its versatile applications in drug delivery, vaccine administration, and disease diagnostics, faces challenges in its complex manufacturing process. Ongoing research and numerous products in development make this market dynamic for newcomers entering the field. “According to the latest BCC Research study, ...
By BCC Research
-
Cutting-edge Homocysteine Methyltransferase, Recombinant for Enhanced Bioprocessing
Creative Enzymes, a leading global supplier and manufacturer of quality enzymes, is thrilled to introduce the availability of Recombinant Homocysteine Methyltransferase, dedicated to assisting researchers and industrial clients to unravel the complexity of enzyme activity. Originated from Pichia pastoris, the Homocysteine Methyltransferase, Recombinant has raised the bar in the field of ...
-
Tris Pharma Partners with Perigon Pharmacy 360 to Enhance Access to DYANAVEL® XR Tablets for the Treatment of Attention Deficit Hyperactivity Disorder
Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced a new partnership with Perigon Pharmacy 360, a full-service, specialty digital pharmacy, to enhance accessibility, affordability and adherence for patients treating symptoms of ADHD with Tris’ ...
-
Multi-Type Animal Cognitive Behavioral Tests for Disease Research
In the pursuit of advancing disease research and its treatment, animal cognitive behavior is studied in a wide range of animal species. The innovative multi-type animal cognitive behavioral tests are set to complement disease research methodology, enabling scientists to gain deeper insight into the complexities of cognitive functioning and its implications in various pathological conditions. ...
By Protheragen
-
Animal Emotional Behavior Tests for Anxiety and Depression Treatment
In today’s fast-paced and stressful society, the prevalence of anxiety and depression has become a significant concern. Emotion-related animal behavior tests aim to provide a good research tool for the study of emotion-associated diseases. Anxiety and depression affect millions of individuals worldwide, leading to a significant burden on public health and impacting overall quality of ...
By Protheragen
-
CD Genomics Unveils Cutting-Edge CRISPR Screen Sequencing Technology
CD Genomics, a distinguished leader in genomics and sequencing services, has proudly unveiled its groundbreaking CRISPR Screen Sequencing technology. This innovative solution promises to expedite discoveries, facilitate target identification, and optimize drug development pipelines within the biotechnology and pharmaceutical industries. CRISPR Screen Sequencing, a genome-wide screening ...
By CD Genomics
-
Tris Pharma Secures First ex-US Authorizations for Quillivant ER Oral Suspension and Quillivant ER Chewable Tablet for the Treatment of Attention Deficit Hyperactivity Disorder
Business Wire – Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain, addiction and neurological disorders, today announced that Health Canada has authorized the use of Quillivant® ER (extended release) for the treatment of attention deficit hyperactivity disorder (ADHD) in children ages 6 to 12. Quillivant ER will be available as both an oral ...
-
CD ComputaBio Launches Revolutionary Antibody De Novo Design Service Pioneering Precision Medicine with AI
CD ComputaBio, a reputable computational service provider in the field of biology, has proudly announced the launch of its Antibody De Novo Design technology, marking a pivotal moment in the field of drug discovery and development. This service harnesses the power of AI to engineer antibodies with unmatched precision, paving the way for targeted therapies, personalized medicine, and cutting-edge ...
-
Semper Paratus Acquisition Corporation Files Registration Statement on Form S-4 in Connection with Proposed Business Combination with Tevogen Bio Inc
Semper Paratus Acquisition Corporation (Nasdaq: LGST) (“Semper Paratus”), a publicly traded special purpose acquisition company, today announced the filing of a registration statement on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission relating to Semper Paratus’ previously announced proposed business combination with Tevogen ...
By Tevogen Bio
-
Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference
Positive results confirm findings from prior studies evaluating the abuse potential of cebranopadol, further highlighting its potential as a safe and potent alternative to traditional opioids Registrational phase 3 clinical trials of cebranopadol in moderate to severe acute pain are on track to initiate in Q4 2023 – Business Wire – Tris Pharma, Inc. (Tris), a commercial-stage ...
-
7-year-old Boy Managing His Hydrocephalus with ReFlow Ventricular System “Gen 1” Featured on Charleston’s ABC News 4
After struggling to conceive a child for what felt like ages, Miranda of Moncks County, South Carolina finally fell pregnant - a miracle that quickly turned into horror when she delivered at 24 weeks in late 2015. At just 1 pound and 12 ounces, her son, Sutton, arrived with life-threatening health issues, including hydrocephalus - a neurological disorder caused by an abnormal buildup of ...
-
CD Bioparticles Announces New PLGA-Based Drug Delivery Systems for In Vitro and In Vivo Applications
With years of experience in the pharmaceutical and life science sectors, CD Bioparticles has recently launched its new line of PLGA-based drug delivery systems for in vitro and in vivo applications, including biocompatible and biodegradable PLGA nanoparticles with different surface modifications (e.g., COOH groups, methoxy PEG, and PEG-azide). In recent years, the development of nanotechnology ...
-
Creative Proteomics Launches Crotonylation Proteomics Analysis Service to Enhance Your Epigenetic Research
Creative Proteomics, a leading provider of proteomics, metabolomics, and bioinformatics services, is pleased to announce the launch of its new Crotonylation Proteomics Analysis Service. This service is designed to provide researchers with a comprehensive and in-depth analysis of crotonylation, a newly discovered post-translational modification (PTM) of lysine residues. Crotonylation, a recently ...
-
Tris Pharma Expands Leadership Team as Company Broadens Commercial Portfolio and Progresses Clinical Pipeline
Thomas Englese, a 20+ year industry veteran with a track record of success at leading biopharmaceutical companies, joins as chief commercial officer Marc Lesnick, Ph.D., appointed as chief development officer, bringing more than 20 years of experience in multiple therapeutic areas Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological ...
-
CanaQuest and Neeka Health Sign Agreement to Conduct Clinical Studies with Mentanine
Canaquest Medical Corp (OTC:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced the signing of a Master Service Agreement with Neeka Health (“Neeka”) that will encompass multiple clinical studies to evaluate the ...
-
BIOtechNOW featured IVS’s participating BIO Innovation Zone
BIOtechNOW featured IVS’s participating BIO Innovation Zone Later this month in Philadelphia at the BIO International Convention, BIO will be partnering with the National Institutes of Health (NIH) and the National Science Foundation (NSF) to host the 2nd annual, newly-expanded BIO Innovation Zone. The Zone will feature Small Business Innovation Research (SBIR) funded early-stage biotech ...
-
Lifespin Announces Expansion of Laboratory Testing Capability
Lifespin GmbH, based in Regensburg (Germany), with offices in Boston, Massachusetts, announced today that it has installed additional Nuclear Magnetic Resonance (NMR) equipment which will double Lifespin’s annual laboratory testing capacity. Lifespin will now be able to scan and create the corresponding digitized, quantitative metabolic profiles involving as many as 300,000 human samples ...
-
Bened Biomedical Completes $10M Series A, Set for Expansion into US Healthcare Market
Medical probiotic leader Bened Biomedical Co., Ltd., which develops and markets neuroactive probiotic products, announced a completed Series A round of fundraising, receiving more than $10 million of capital from two prominent investors, Trans-Pacific Technology Fund (TPTF) and JAFCO Asia. With strategic support from these venture capital partners, Bened expects to rapidly expand its ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you